Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Exubera® (Inhaled Insulin) Compared With Subcutaneous Human Insulin Therapy in Adult Subjects With Type 2 Diabetes Mellitus: A Long-Term, Outpatient, Open-Label, Parallel-Group Comparative Trial

NCT00136916 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00136916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00136916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Exubera® (Inhaled Insulin) Compared With Subcutaneous Human Insulin Therapy in Adult Subjects With Type 2 Diabetes Mellitus: A Long-Term, Outpatient, Open-Label, Parallel-Group Comparative Trial
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2002
Completion date
December 31, 2008
Enrollment
635 (actual)
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus